Tirzepatide in Australia

Dual GIP and GLP-1 receptor agonist. Tirzepatide is a peptide of 39 amino acids that switches on both the GIP and the GLP-1 receptor. As the first dual incretin agonist to finish Phase 3 development, it is now registered as a prescription medicine across many countries. The research-grade vial offered here is the unformulated peptide intended for laboratory use, not the branded pen.

Glycaemic control: fasting glucose and HbA1c tracked throughout the SURPASS trials. Body composition: dEXA sub-studies separating fat mass from lean mass. Appetite signalling: satiety and food-intake measures taken in Phase 1 pharmacology. Hepatic fat: liver-fat fraction read by MRI-PDFF in the MASLD studies. Cardiovascular outcomes: the SURPASS-CVOT and SUMMIT programs. In type 2 diabetes the SURPASS trials and in obesity the SURMOUNT trials reported HbA1c drops of about 2 percentage points and average weight reductions reaching 22.5% at the top dose across 72 weeks (SURMOUNT-1, Jastreboff et al., NEJM 2022). Studies that followed looked at sleep apnoea, heart failure with preserved ejection fraction and MASLD.

SURMOUNT-1 recorded average weight reductions of 15.0%, 19.5% and 20.9% at 5, 10 and 15mg weekly over 72 weeks (22.5% on the treatment-regimen estimand) against 3.1% for placebo, and the SURPASS trials reported HbA1c reductions near 2 percentage points. Body-composition sub-studies traced about three quarters of the weight lost to fat mass.

The trials saw gastrointestinal events most often, namely nausea, diarrhoea, reduced appetite, vomiting and constipation, usually mild to moderate and arising while the dose was being escalated. Labelling for the registered product flags pancreatitis, gallbladder disease, hypoglycaemia when combined with insulin secretagogues, and a boxed warning on thyroid C-cell tumours drawn from rodent findings.

In the published Tirzepatide research, the amounts used were 5, 10 or 15 mg, Once weekly in human, phase 3, type 2 diabetes (Rosenstock J et al. (2021)); 5, 10 or 15 mg, started at 2.5 mg and raised by 2.5 mg every 4 weeks, Once weekly, subcutaneous in human, phase 3, type 2 diabetes on metformin (Ludvik B et al. (2021)); 5, 10 or 15 mg, started at 2.5 mg and raised by 2.5 mg every 4 weeks, Once weekly, subcutaneous in human, phase 3, type 2 diabetes on insulin glargine (Dahl D et al. (2022)). These are the figures each study reports for its own model, listed in full in the dosage table on this page with links to PubMed. Peptide Aus supplies Tirzepatide for in-vitro research and does not give dosing guidance for people.

Retatrutide layers glucagon receptor activity over the GLP-1 and GIP profile of tirzepatide and reported bigger weight loss in its Phase 2 trial; tirzepatide, however, is the one approved as a medicine.

The two met head-to-head in SURPASS-2 in type 2 diabetes, where tirzepatide beat semaglutide 1mg on both HbA1c and weight at each of its three doses.

Mounjaro is the registered tirzepatide pen for prescription use. The research vial holds the same peptide as unformulated lyophilised powder for laboratory work and does not stand in for it.

The active peptide is the same, but the product is not. Mounjaro is a registered, sterile, dose-metered injection made under pharmaceutical GMP for use on prescription. What you see here is unformulated research-grade tirzepatide for laboratory study, and it is not a replacement for a prescribed medicine.

Pick the 20mg vial for short assays and method development. The 40mg and 60mg vials cut down on how often you reconstitute over a longer protocol and work out cheaper per milligram. Every size ships with its own certificate of analysis.

With bacteriostatic water added slowly down the inside wall of the vial, then swirled gently. Each vial size lists its suggested volume, and the calculator converts volume to concentration.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

Supplied as the registered product, tirzepatide is a Schedule 4 prescription-only medicine in Australia. Research-grade tirzepatide powder is a different thing altogether and has no approval for human use. Peptide Aus provides it only for in-vitro laboratory research.

Directly from Peptide Aus, from Australian stock, in 3 vial sizes from $249.99 (20mg) to $349.99 (60mg). Prices are AUD and GST inclusive. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.

It depends on the vial size: 20mg takes 2 mL, 40mg takes 2 mL, 60mg takes 3 mL. That gives 10 mg/mL, 20 mg/mL, 20 mg/mL respectively. The reconstitution steps on this page and the calculator cover the rest.